{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:56:23Z","timestamp":1790898983770,"version":"4.1.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2008,3,13]],"date-time":"2008-03-13T00:00:00Z","timestamp":1205366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s00198-008-0575-5","type":"journal-article","created":{"date-parts":[[2008,3,12]],"date-time":"2008-03-12T20:09:16Z","timestamp":1205352556000},"page":"1125-1138","source":"Crossref","is-referenced-by-count":38,"title":["Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis"],"prefix":"10.1007","volume":"19","author":[{"given":"T. J.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. A.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. W.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,3,13]]},"reference":[{"key":"575_CR1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","volume":"359","author":"PD Delmas","year":"2002","unstructured":"Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018\u20132026","journal-title":"Lancet"},{"key":"575_CR2","first-page":"315","volume-title":"Osteoporosis","author":"AM Parfitt","year":"1996","unstructured":"Parfitt AM (1996) Skeletal heterogeneity and the purposes of bone remodelling: implications for the understanding of osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic, San Diego, pp 315\u2013339"},{"key":"575_CR3","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","volume":"354","author":"E Seeman","year":"2006","unstructured":"Seeman E, Delmas PD (2006) Bone quality\u2014the material and structural basis of bone strength and fragility. N Engl J Med 354:2250\u20132261","journal-title":"N Engl J Med"},{"key":"575_CR4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1359\/jbmr.2001.16.3.457","volume":"16","author":"JC Linden van der","year":"2001","unstructured":"Van der Linden JC, Homminga J, Verhaar JA, Weinans H (2001) Mechanical consequences of bone loss in cancellous bone. J Bone Miner Res 16:457\u2013465","journal-title":"J Bone Miner Res"},{"key":"575_CR5","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1359\/jbmr.2001.16.9.1575","volume":"16","author":"EM Hauge","year":"2001","unstructured":"Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F (2001) Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 16:1575\u20131582","journal-title":"J Bone Miner Res"},{"key":"575_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.060910","volume":"22","author":"EF Eriksen","year":"2007","unstructured":"Eriksen EF, Eghbali-Fatourechi GZ, Khosla S (2007) Remodeling and vascular spaces in bone. J Bone Miner Res 22:1\u20136","journal-title":"J Bone Miner Res"},{"key":"575_CR7","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa044264","volume":"352","author":"GZ Eghbali-Fatourechi","year":"2005","unstructured":"Eghbali-Fatourechi GZ, Lamsam J, Fraser D, Nagel D, Riggs BL, Khosla S (2005) Circulating osteoblast-lineage cells in humans. N Engl J Med 352:1959\u20131966","journal-title":"N Engl J Med"},{"issue":"2","key":"575_CR8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/jcb.21423","volume":"103","author":"UI Modder","year":"2008","unstructured":"Modder UI, Khosla S (2008) Skeletal stem\/osteoprogenitor cells: current concepts, alternate hypotheses, and relationship to the bone remodeling compartment. J Cell Biochem 103(2):393\u2013400","journal-title":"J Cell Biochem"},{"key":"575_CR9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"575_CR10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF02013227","volume":"26","author":"P Lips","year":"1978","unstructured":"Lips P, Courpron P, Meunier PJ (1978) Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res 26:13\u201317","journal-title":"Calcif Tissue Res"},{"key":"575_CR11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0221-8747(82)90032-7","volume":"4","author":"S Vedi","year":"1982","unstructured":"Vedi S, Compston JE, Webb A, Tighe JR (1982) Histomorphometric analysis of bone biopsies from the iliac crest of normal British subjects. Metab Bone Dis Relat Res 4:231\u2013236","journal-title":"Metab Bone Dis Relat Res"},{"key":"575_CR12","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1359\/jbmr.2002.17.9.1570","volume":"17","author":"DD Bikle","year":"2002","unstructured":"Bikle DD, Sakata T, Leary C et al (2002) Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 17:1570\u20131578","journal-title":"J Bone Miner Res"},{"key":"575_CR13","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1210\/endo.142.10.8436","volume":"142","author":"N Miyakoshi","year":"2001","unstructured":"Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S (2001) Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 142:4349\u20134356","journal-title":"Endocrinology"},{"key":"575_CR14","doi-asserted-by":"crossref","first-page":"44005","DOI":"10.1074\/jbc.M208265200","volume":"277","author":"M Zhang","year":"2002","unstructured":"Zhang M, Xuan S, Bouxsein MLet al (2002) Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signalling in bone matrix mineralization. J Biol Chem 277:44005\u201344012","journal-title":"J Biol Chem"},{"key":"575_CR15","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1359\/jbmr.070517","volume":"22","author":"Y Wang","year":"2007","unstructured":"Wang Y, Nishida S, Boudignon BM et al (2007) IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J Bone Miner Res 22:1329\u20131337","journal-title":"J Bone Miner Res"},{"key":"575_CR16","first-page":"1384","volume":"77","author":"PR Ebeling","year":"1993","unstructured":"Ebeling PR, Jones JD, O\u2019Fallon WM, Janes CH, Riggs BL (1993) Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women. J Clin Endocrinol Metab 77:1384\u20131387","journal-title":"J Clin Endocrinol Metab"},{"key":"575_CR17","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","volume":"104","author":"RL Jilka","year":"1999","unstructured":"Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC (1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439\u2013446","journal-title":"J Clin Invest"},{"key":"575_CR18","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1359\/jbmr.070518","volume":"22","author":"RL Jilka","year":"2007","unstructured":"Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC (2007) Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res 22:1492\u20131501","journal-title":"J Bone Miner Res"},{"key":"575_CR19","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1172\/JCI24918","volume":"115","author":"D Miao","year":"2005","unstructured":"Miao D, He B, Jiang Y et al (2005) Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1\u201334. J Clin Invest 115:2402\u20132411","journal-title":"J Clin Invest"},{"key":"575_CR20","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1210\/endo.141.7.7585","volume":"141","author":"G Zhao","year":"2000","unstructured":"Zhao G, Monier-Faugere MC, Langub MC et al (2000) Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 141:2674\u20132682","journal-title":"Endocrinology"},{"key":"575_CR21","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","volume":"102","author":"RS Weinstein","year":"1998","unstructured":"Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274\u2013282","journal-title":"J Clin Invest"},{"key":"575_CR22","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1210\/endo.142.7.8306","volume":"142","author":"G Karsenty","year":"2001","unstructured":"Karsenty G (2001) Minireview: transcriptional control of osteoblast differentiation. Endocrinology 142:2731\u20132733","journal-title":"Endocrinology"},{"key":"575_CR23","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1101\/gad.13.8.1025","volume":"13","author":"P Ducy","year":"1999","unstructured":"Ducy P, Starbuck M, Priemel M et al (1999) A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 13:1025\u20131036","journal-title":"Genes Dev"},{"key":"575_CR24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1210\/me.2002-0225","volume":"17","author":"V Krishnan","year":"2003","unstructured":"Krishnan V, Moore TL, Ma YL et al (2003) Parathyroid hormone bone anabolic action requires Cbfa1\/Runx2-dependent signalling. Mol Endocrinol 17:423\u2013435","journal-title":"Mol Endocrinol"},{"key":"575_CR25","doi-asserted-by":"crossref","first-page":"6222","DOI":"10.1128\/MCB.22.17.6222-6233.2002","volume":"22","author":"V Geoffroy","year":"2002","unstructured":"Geoffroy V, Kneissel M, Fournier B, Boyde A, Matthias P (2002) High bone resorption in adult aging transgenic mice overexpressing cbfa1\/runx2 in cells of the osteoblastic lineage. Mol Cell Biol 22:6222\u20136233","journal-title":"Mol Cell Biol"},{"key":"575_CR26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0092-8674(01)00622-5","volume":"108","author":"K Nakashima","year":"2002","unstructured":"Nakashima K, Zhou X, Kunkel G et al (2002) The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108:17\u201329","journal-title":"Cell"},{"key":"575_CR27","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.bone.2006.09.008","volume":"40","author":"JE Compston","year":"2007","unstructured":"Compston JE (2007) Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 40:1447\u20131452","journal-title":"Bone"},{"key":"575_CR28","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","volume":"40","author":"RL Jilka","year":"2007","unstructured":"Jilka RL (2007) Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434\u20131446","journal-title":"Bone"},{"key":"575_CR29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S8756-3282(03)00202-3","volume":"33","author":"CA Frolik","year":"2003","unstructured":"Frolik CA, Black EC, Cain RL et al (2003) Anabolic and catabolic bone effects of human parathyroid hormone (1\u201334) are predicted by duration of hormone exposure. Bone 33:372\u2013379","journal-title":"Bone"},{"key":"575_CR30","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1210\/endo.136.8.7628403","volume":"136","author":"H Dobnig","year":"1995","unstructured":"Dobnig H, Turner RT (1995) Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632\u20133638","journal-title":"Endocrinology"},{"key":"575_CR31","doi-asserted-by":"crossref","first-page":"50259","DOI":"10.1074\/jbc.M307444200","volume":"278","author":"T Bellido","year":"2003","unstructured":"Bellido T, Ali AA, Plotkin LI et al (2003) Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signalling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278:50259\u201350272","journal-title":"J Biol Chem"},{"key":"575_CR32","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","volume":"146","author":"T Bellido","year":"2005","unstructured":"Bellido T, Ali AA, Gubrij I et al (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577\u20134583","journal-title":"Endocrinology"},{"key":"575_CR33","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1210\/jc.2002-021597","volume":"88","author":"DM Shoback","year":"2003","unstructured":"Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M (2003) The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 88:5644\u20135649","journal-title":"J Clin Endocrinol Metab"},{"key":"575_CR34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0022-3565(24)29333-2","volume":"299","author":"EF Nemeth","year":"2001","unstructured":"Nemeth EF, Delmar EG, Heaton WL et al (2001) Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther 299:323\u2013331","journal-title":"J Pharmacol Exp Ther"},{"key":"575_CR35","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1172\/JCI9038","volume":"105","author":"M Gowen","year":"2000","unstructured":"Gowen M, Stroup GB, Dodds RA et al (2000) Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 105:1595\u20131604","journal-title":"J Clin Invest"},{"key":"575_CR36","first-page":"S88","volume":"22","author":"S Kumar","year":"2007","unstructured":"Kumar S, Liang X, Vasko JA et al (2007) Oral treatment with calcium receptor antagonist SB-423557 causes PTH release in multiple species and positive bone forming effects in the rat. J Bone Miner Res 22:S88","journal-title":"J Bone Miner Res"},{"key":"575_CR37","first-page":"S128","volume":"22","author":"D Ethgen","year":"2007","unstructured":"Ethgen D, Danoff, Schultz et al (2007) Antagonism of a calcium sensing receptor stimulates dose-related release of endogenous parathyroid hormone in normal volunteers: a proof of concept study. J Bone Miner Res 22:S128","journal-title":"J Bone Miner Res"},{"key":"575_CR38","first-page":"S38","volume":"22","author":"D Ethgen","year":"2007","unstructured":"Ethgen D, Phillips JC, Matheny C et al (2007) Dose-dependent increases in endogenous parathyroid hormone concentration after administration of a calcium-sensing receptor antagonist to normal volunteers for an oral bone forming agent. J Bone Miner Res 22:S38","journal-title":"J Bone Miner Res"},{"key":"575_CR39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1152\/physrev.1996.76.1.127","volume":"76","author":"WM Philbrick","year":"1996","unstructured":"Philbrick WM, Wysolmerski JJ, Galbraith S (1996) Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev 76:127\u2013173","journal-title":"Physiol Rev"},{"issue":"Suppl","key":"575_CR40","first-page":"S23","volume":"154","author":"TJ Martin","year":"1997","unstructured":"Martin TJ, Moseley JM, Williams ED (1997) Parathyroid hormone-related protein: hormone and cytokine. J Endocrinol 154 [Suppl]:S23\u2013S37","journal-title":"J Endocrinol"},{"key":"575_CR41","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1210\/endo-125-4-2022","volume":"125","author":"JM Hock","year":"1989","unstructured":"Hock JM, Fonseca J, Gunness-Hey M, Kemp BE, Martin TJ (1989) Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1\u201334 and PTH 1\u201334 on bone in rats. Endocrinology 125:2022\u20132027","journal-title":"Endocrinology"},{"key":"575_CR42","first-page":"199","volume":"81","author":"M Everhart-Caye","year":"1996","unstructured":"Everhart-Caye M, Inzucchi SE, Guinness-Henry J, Mitnick MA, Stewart AF (1996) Parathyroid hormone (PTH)-related protein(1\u201336) is equipotent to PTH(1\u201334) in humans. J Clin Endocrinol Metab 81:199\u2013208","journal-title":"J Clin Endocrinol Metab"},{"key":"575_CR43","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1210\/jc.2002-021122","volume":"88","author":"MJ Horwitz","year":"2003","unstructured":"Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF (2003) Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:569\u2013575","journal-title":"J Clin Endocrinol Metab"},{"key":"575_CR44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/8756-3282(93)90190-L","volume":"14","author":"AB Hodsman","year":"1993","unstructured":"Hodsman AB, Steer BM (1993) Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces. Bone 14:523\u2013527","journal-title":"Bone"},{"key":"575_CR45","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1359\/jbmr.070616","volume":"22","author":"PJ Kostenuik","year":"2007","unstructured":"Kostenuik PJ, Ferrari S, Pierroz D et al (2007) Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone. J Bone Miner Res 22:1534\u20131547","journal-title":"J Bone Miner Res"},{"key":"575_CR46","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1083\/jcb.126.6.1611","volume":"126","author":"N Amizuka","year":"1994","unstructured":"Amizuka N, Warshawsky H, Henderson JE, Goltzman D, Karaplis AC (1994) Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J Cell Biol 126:1611\u20131623","journal-title":"J Cell Biol"},{"key":"575_CR47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S8756-3282(97)00180-4","volume":"21","author":"V Kartsogiannis","year":"1997","unstructured":"Kartsogiannis V, Moseley J, McKelvie B et al (1997) Temporal expression of PTHrP during endochondral bone formation in mouse and intramembranous bone formation in an in vivo rabbit model. Bone 21:385\u2013392","journal-title":"Bone"},{"key":"575_CR48","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/(SICI)1097-4652(199601)166:1<94::AID-JCP11>3.0.CO;2-P","volume":"166","author":"N Suda","year":"1996","unstructured":"Suda N, Gillespie MT, Traianedes K et al (1996) Expression of parathyroid hormone-related protein in cells of osteoblast lineage. J Cell Physiol 166:94\u2013104","journal-title":"J Cell Physiol"},{"key":"575_CR49","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/dbio.1996.0104","volume":"175","author":"N Amizuka","year":"1996","unstructured":"Amizuka N, Karaplis AC, Henderson JE (1996) Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev Biol 175:166\u2013176","journal-title":"Dev Biol"},{"key":"575_CR50","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","volume":"18","author":"Y Jiang","year":"2003","unstructured":"Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1\u201334) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932\u20131941","journal-title":"J Bone Miner Res"},{"key":"575_CR51","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1043-2760(01)00460-X","volume":"12","author":"E Seeman","year":"2001","unstructured":"Seeman E, Delmas PD (2001) Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab 12:281\u2013283","journal-title":"Trends Endocrinol Metab"},{"key":"575_CR52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.molmed.2004.12.004","volume":"11","author":"TJ Martin","year":"2005","unstructured":"Martin TJ, Sims NA (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76\u201381","journal-title":"Trends Mol Med"},{"key":"575_CR53","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/jbmr.070109","volume":"22","author":"MA Karsdal","year":"2007","unstructured":"Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K (2007) Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 22:487\u2013494","journal-title":"J Bone Miner Res"},{"key":"575_CR54","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1359\/JBMR.051109","volume":"21","author":"R Lindsay","year":"2006","unstructured":"Lindsay R, Cosman F, Zhou H et al (2006) A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 21:366\u2013373","journal-title":"J Bone Miner Res"},{"key":"575_CR55","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1210\/jc.2003-1703","volume":"90","author":"H Dobnig","year":"2005","unstructured":"Dobnig H, Sipos A, Jiang Y et al (2005) Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970\u20133977","journal-title":"J Clin Endocrinol Metab"},{"key":"575_CR56","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1210\/en.2005-0333","volume":"146","author":"AJ Koh","year":"2005","unstructured":"Koh AJ, Demiralp B, Neiva KG et al (2005) Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146:4584\u20134596","journal-title":"Endocrinology"},{"key":"575_CR57","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bone.2003.12.022","volume":"34","author":"PD Delmas","year":"2004","unstructured":"Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599\u2013604","journal-title":"Bone"},{"key":"575_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","volume":"17","author":"S Sarkar","year":"2002","unstructured":"Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1\u201310","journal-title":"J Bone Miner Res"},{"key":"575_CR59","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745\u2013751","journal-title":"J Bone Miner Res"},{"key":"575_CR60","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE et al (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207\u20131215","journal-title":"N Engl J Med"},{"key":"575_CR61","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","volume":"349","author":"JS Finkelstein","year":"2003","unstructured":"Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216\u20131226","journal-title":"N Engl J Med"},{"key":"575_CR62","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","volume":"353","author":"F Cosman","year":"2005","unstructured":"Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566\u2013575","journal-title":"N Engl J Med"},{"key":"575_CR63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.tem.2004.01.002","volume":"15","author":"TJ Martin","year":"2004","unstructured":"Martin TJ (2004) Does bone resorption inhibition affect the anabolic response to parathyroid hormone? Trends Endocrinol Metab 15:49\u201350","journal-title":"Trends Endocrinol Metab"},{"key":"575_CR64","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","volume":"353","author":"DM Black","year":"2005","unstructured":"Black DM, Bilezikian JP, Ensrud KE et al (2005) One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis. N Engl J Med 353:555\u2013565","journal-title":"N Engl J Med"},{"key":"575_CR65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev.cellbio.14.1.59","volume":"14","author":"A Wodarz","year":"1998","unstructured":"Wodarz A, Nusse R (1998) Mechanisms of Wnt signalling in development. Annu Rev Cell Dev Biol 14:59\u201388","journal-title":"Annu Rev Cell Dev Biol"},{"key":"575_CR66","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1006\/excr.1999.4710","volume":"253","author":"M Uusitalo","year":"1999","unstructured":"Uusitalo M, Heikkila M, Vainio S (1999) Molecular genetic studies of Wnt signalling in the mouse. Exp Cell Res 253:336\u2013348","journal-title":"Exp Cell Res"},{"key":"575_CR67","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gene.2004.06.044","volume":"341","author":"JJ Westendorf","year":"2004","unstructured":"Westendorf JJ, Kahler RA, Schroeder TM (2004) Wnt signalling in osteoblasts and bone diseases. Gene 341:19\u201339","journal-title":"Gene"},{"key":"575_CR68","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","volume":"127","author":"H Clevers","year":"2006","unstructured":"Clevers H (2006) Wnt\/beta-catenin signalling in development and disease. Cell 127:469\u2013480","journal-title":"Cell"},{"key":"575_CR69","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S0960-9822(02)70716-1","volume":"6","author":"J Yang-Snyder","year":"1996","unstructured":"Yang-Snyder J, Miller JR, Brown JD, Lai CJ, Moon RT (1996) A frizzled homolog functions in a vertebrate Wnt signalling pathway. Curr Biol 6:1302\u20131306","journal-title":"Curr Biol"},{"key":"575_CR70","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/37138","volume":"390","author":"DC Slusarski","year":"1997","unstructured":"Slusarski DC, Corces VG, Moon RT (1997) Interaction of Wnt and a Frizzled homologue triggers G-protein-linked phosphatidylinositol signalling. Nature 390:410\u2013413","journal-title":"Nature"},{"key":"575_CR71","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1126\/science.275.5306.1652","volume":"275","author":"X He","year":"1997","unstructured":"He X, Saint-Jeannet JP, Wang Y, Nathans J, Dawid I, Varmus H (1997) A member of the Frizzled protein family mediating axis induction by Wnt-5A. Science 275:1652\u20131654","journal-title":"Science"},{"key":"575_CR72","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1073\/pnas.96.7.3546","volume":"96","author":"JC Hsieh","year":"1999","unstructured":"Hsieh JC, Rattner A, Smallwood PM, Nathans J (1999) Biochemical characterization of Wnt-frizzled interactions using a soluble, biologically active vertebrate Wnt protein. Proc Natl Acad Sci USA 96:3546\u20133551","journal-title":"Proc Natl Acad Sci USA"},{"key":"575_CR73","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/35035124","volume":"407","author":"KI Pinson","year":"2000","unstructured":"Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC (2000) An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407:535\u2013538","journal-title":"Nature"},{"key":"575_CR74","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/35077108","volume":"411","author":"B Mao","year":"2001","unstructured":"Mao B, Wu W, Li Y et al (2001) LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411:321\u2013325","journal-title":"Nature"},{"key":"575_CR75","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1097-2765(01)00224-6","volume":"7","author":"J Mao","year":"2001","unstructured":"Mao J, Wang J, Liu B et al (2001) Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signalling pathway. Mol Cell 7:801\u2013809","journal-title":"Mol Cell"},{"key":"575_CR76","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","volume":"107","author":"Y Gong","year":"2001","unstructured":"Gong Y, Slee RB, Fukai N et al (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513\u2013523","journal-title":"Cell"},{"key":"575_CR77","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","volume":"346","author":"LM Boyden","year":"2002","unstructured":"Boyden LM, Mao J, Belsky J et al (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513\u20131521","journal-title":"N Engl J Med"},{"key":"575_CR78","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1126\/science.1136370","volume":"315","author":"A Mani","year":"2007","unstructured":"Mani A, Radhakrishnan J, Wang H et al (2007) LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315:1278\u20131282","journal-title":"Science"},{"key":"575_CR79","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1210\/en.2006-1352","volume":"148","author":"W Balemans","year":"2007","unstructured":"Balemans W, Van Hul W (2007) The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. Endocrinology 148:2622\u20132629","journal-title":"Endocrinology"},{"key":"575_CR80","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bone.2006.03.017","volume":"39","author":"J Li","year":"2006","unstructured":"Li J, Sarosi I, Cattley RC et al (2006) Dkk1-mediated inhibition of Wnt signalling in bone results in osteopenia. Bone 39:754\u2013766","journal-title":"Bone"},{"key":"575_CR81","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1083\/jcb.200201089","volume":"157","author":"M Kato","year":"2002","unstructured":"Kato M, Patel MS, Levasseur R et al (2002) Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157:303\u2013314","journal-title":"J Cell Biol"},{"key":"575_CR82","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1359\/jbmr.2003.18.6.960","volume":"18","author":"P Babij","year":"2003","unstructured":"Babij P, Zhao W, Small C et al (2003) High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18:960\u2013974","journal-title":"J Bone Miner Res"},{"key":"575_CR83","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1359\/jbmr.2003.18.10.1842","volume":"18","author":"G Rawadi","year":"2003","unstructured":"Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S (2003) BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 18:1842\u20131853","journal-title":"J Bone Miner Res"},{"key":"575_CR84","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1359\/JBMR.040816","volume":"19","author":"ML Johnson","year":"2004","unstructured":"Johnson ML, Harnish K, Nusse R, Van Hul W (2004) LRP5 and Wnt signalling: a union made for bone. J Bone Miner Res 19:1749\u20131757","journal-title":"J Bone Miner Res"},{"key":"575_CR85","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/jcb.20253","volume":"94","author":"G Mbalaviele","year":"2005","unstructured":"Mbalaviele G, Sheikh S, Stains JP et al (2005) Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem 94:403\u2013418","journal-title":"J Cell Biochem"},{"key":"575_CR86","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.devcel.2006.11.003","volume":"12","author":"X Tu","year":"2007","unstructured":"Tu X, Joeng KS, Nakayama KI et al (2007) Noncanonical Wnt signalling through G protein-linked PKCdelta activation promotes bone formation. Dev Cell 12:113\u2013127","journal-title":"Dev Cell"},{"key":"575_CR87","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/ncb1647","volume":"9","author":"I Takada","year":"2007","unstructured":"Takada I, Mihara M, Suzawa M et al (2007) A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol 9:1273\u20131285","journal-title":"Nat Cell Biol"},{"key":"575_CR88","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","volume":"10","author":"W Balemans","year":"2001","unstructured":"Balemans W, Ebeling M, Patel N et al (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537\u2013543","journal-title":"Hum Mol Genet"},{"key":"575_CR89","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","volume":"39","author":"W Balemans","year":"2002","unstructured":"Balemans W, Patel N, Ebeling M et al (2002) Identification of a 52\u00a0kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39:91\u201397","journal-title":"J Med Genet"},{"key":"575_CR90","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1101\/gr.3437105","volume":"15","author":"GG Loots","year":"2005","unstructured":"Loots GG, Kneissel M, Keller H et al (2005) Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15:928\u2013935","journal-title":"Genome Res"},{"key":"575_CR91","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1210\/jc.2005-1235","volume":"90","author":"JC Gardner","year":"2005","unstructured":"Gardner JC, van Bezooijen RL, Mervis B et al (2005) Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 90:6392\u20136395","journal-title":"J Clin Endocrinol Metab"},{"key":"575_CR92","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1210\/jc.2003-030201","volume":"88","author":"JE Wergedal","year":"2003","unstructured":"Wergedal JE, Veskovic K, Hellan M et al (2003) Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 88:5778\u20135783","journal-title":"J Clin Endocrinol Metab"},{"key":"575_CR93","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","volume":"22","author":"DG Winkler","year":"2003","unstructured":"Winkler DG, Sutherland MK, Geoghegan JC et al (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267\u20136276","journal-title":"EMBO J"},{"key":"575_CR94","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","volume":"199","author":"RL Bezooijen van","year":"2004","unstructured":"Van Bezooijen RL, Roelen BA, Visser A et al (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805\u2013814","journal-title":"J Exp Med"},{"key":"575_CR95","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","volume":"19","author":"KE Poole","year":"2005","unstructured":"Poole KE, van Bezooijen RL, Loveridge N et al (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842\u20131844","journal-title":"FASEB J"},{"key":"575_CR96","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","volume":"37","author":"H Keller","year":"2005","unstructured":"Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone. Bone 37:148\u2013158","journal-title":"Bone"},{"key":"575_CR97","first-page":"354","volume":"6","author":"AG Robling","year":"2006","unstructured":"Robling AG, Bellido T, Turner CH (2006) Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J Musculoskelet Neuronal Interact 6:354","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"575_CR98","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","volume":"280","author":"X Li","year":"2005","unstructured":"Li X, Zhang Y, Kang H et al (2005) Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signalling. J Biol Chem 280:19883\u201319887","journal-title":"J Biol Chem"},{"key":"575_CR99","doi-asserted-by":"crossref","first-page":"13616","DOI":"10.1074\/jbc.M411999200","volume":"280","author":"E Hay","year":"2005","unstructured":"Hay E, Faucheu C, Suc-Royer I et al (2005) Interaction between LRP5 and Frat1 mediates the activation of the Wnt canonical pathway. J Biol Chem 280:13616\u201313623","journal-title":"J Biol Chem"},{"key":"575_CR100","doi-asserted-by":"crossref","first-page":"17406","DOI":"10.1073\/pnas.0505259102","volume":"102","author":"P Clement-Lacroix","year":"2005","unstructured":"Clement-Lacroix P, Ai M, Morvan F et al (2005) Lrp5-independent activation of Wnt signalling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA 102:17406\u201317411","journal-title":"Proc Natl Acad Sci USA"},{"key":"575_CR101","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1359\/jbmr.060316","volume":"21","author":"NH Kulkarni","year":"2006","unstructured":"Kulkarni NH, Onyia JE, Zeng Q et al (2006) Orally bioavailable GSK-3alpha\/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 21:910\u2013920","journal-title":"J Bone Miner Res"},{"issue":"6","key":"575_CR102","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/jcb.21374","volume":"102","author":"NH Kulkarni","year":"2007","unstructured":"Kulkarni NH, Wei T, Kumar A et al (2007) Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor. J Cell Biochem 102(6):1504\u20131518","journal-title":"J Cell Biochem"},{"key":"575_CR103","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","volume":"8","author":"DA Glass II","year":"2005","unstructured":"Glass DA II, Bialek P, Ahn JD et al (2005) Canonical Wnt signalling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751\u2013764","journal-title":"Dev Cell"},{"key":"575_CR104","doi-asserted-by":"crossref","first-page":"21162","DOI":"10.1074\/jbc.M501900200","volume":"280","author":"SL Holmen","year":"2005","unstructured":"Holmen SL, Zylstra CR, Mukherjee A et al (2005) Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 280:21162\u201321168","journal-title":"J Biol Chem"},{"key":"575_CR105","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/35096075","volume":"2","author":"P Cohen","year":"2001","unstructured":"Cohen P, Frame S (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol 2:769\u2013776","journal-title":"Nat Rev Mol Cell Biol"},{"key":"575_CR106","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0092-8674(01)00412-3","volume":"105","author":"AJ Harwood","year":"2001","unstructured":"Harwood AJ (2001) Regulation of GSK-3: a cellular multiprocessor. Cell 105:821\u2013824","journal-title":"Cell"},{"key":"575_CR107","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1359\/jbmr.060311","volume":"21","author":"F Morvan","year":"2006","unstructured":"Morvan F, Boulukos K, Clement-Lacroix P et al (2006) Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21:934\u2013945","journal-title":"J Bone Miner Res"},{"key":"575_CR108","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R et al (2003) The role of the Wnt-signalling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483\u20132494","journal-title":"N Engl J Med"},{"key":"575_CR109","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","volume":"109","author":"S Yaccoby","year":"2007","unstructured":"Yaccoby S, Ling W, Zhan F et al (2007) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109:2106\u20132111","journal-title":"Blood"},{"key":"575_CR110","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1210\/jc.2005-2370","volume":"90","author":"SM Ott","year":"2005","unstructured":"Ott SM (2005) Sclerostin and Wnt signaling\u2014the pathway to bone strength. J Clin Endocrinol Metab 90:6741\u20136743","journal-title":"J Clin Endocrinol Metab"},{"key":"575_CR111","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1359\/jbmr.06s218","volume":"21","author":"M Ominsky","year":"2006","unstructured":"Ominsky M, Stouch B, Doellgast G et al (2006) Administration of sclerostin monoclonal antibodies to female cynomolgus monkeys results in increased bone formation, bone mineral density and bone strength. J Bone Miner Res 21:S94","journal-title":"J Bone Miner Res"},{"key":"575_CR112","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1359\/jbmr.061005","volume":"22","author":"D Padhi","year":"2007","unstructured":"Padhi D, Stouch B, Jang G et al (2007) Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Res 22:S37","journal-title":"J Bone Miner Res"},{"key":"575_CR113","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10735-007-9096-3","volume":"38","author":"G Silvestrini","year":"2007","unstructured":"Silvestrini G, Ballanti P, Leopizzi M et al (2007) Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 38:261\u2013269","journal-title":"J Mol Histol"},{"key":"575_CR114","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cytogfr.2005.02.005","volume":"16","author":"RL Bezooijen van","year":"2005","unstructured":"Van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW (2005) SOST\/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16:319\u2013327","journal-title":"Cytokine Growth Factor Rev"},{"key":"575_CR115","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bone.2004.05.023","volume":"35","author":"MK Sutherland","year":"2004","unstructured":"Sutherland MK, Geoghegan JC, Yu C et al (2004) Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35:828\u2013835","journal-title":"Bone"},{"issue":"12","key":"575_CR116","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1359\/jbmr.070804","volume":"22","author":"O Leupin","year":"2007","unstructured":"Leupin O, Kramer I, Collette NM et al (2007) Control of the SOST bone enhancer by PTH via MEF2 transcription factors. J Bone Miner Res 22(12):1957\u20131967","journal-title":"J Bone Miner Res"},{"key":"575_CR117","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1126\/science.1144090","volume":"317","author":"AS Brack","year":"2007","unstructured":"Brack AS, Conboy MJ, Roy S et al (2007) Increased Wnt signalling during aging alters muscle stem cell fate and increases fibrosis. Science 317:807\u2013810","journal-title":"Science"},{"key":"575_CR118","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.1143578","volume":"317","author":"H Liu","year":"2007","unstructured":"Liu H, Fergusson MM, Castilho RM et al (2007) Augmented Wnt signalling in a mammalian model of accelerated aging. Science 317:803\u2013806","journal-title":"Science"},{"key":"575_CR119","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/dvdy.20672","volume":"235","author":"T Holowacz","year":"2006","unstructured":"Holowacz T, Zeng L, Lassar AB (2006) Asymmetric localization of numb in the chick somite and the influence of myogenic signals. Dev Dyn 235:633\u2013645","journal-title":"Dev Dyn"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-008-0575-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-008-0575-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-008-0575-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T02:30:46Z","timestamp":1738117846000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-008-0575-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,13]]},"references-count":119,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["575"],"URL":"https:\/\/doi.org\/10.1007\/s00198-008-0575-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,13]]}}}